RT Journal Article SR Electronic T1 Relationship Between 18F-FDG Accumulation and Lactate Dehydrogenase A Expression in Lung Adenocarcinomas JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1766 OP 1771 DO 10.2967/jnumed.114.145490 VO 55 IS 11 A1 Xiang Zhou A1 Ruohua Chen A1 Wenhui Xie A1 Yicheng Ni A1 Jianjun Liu A1 Gang Huang YR 2014 UL http://jnm.snmjournals.org/content/55/11/1766.abstract AB 18F-FDG PET has been widely used in the management of malignant tumors. Lactate dehydrogenase A (LDHA) plays an important role in the development, invasion, and metastasis of malignancies. However, the relationship between 18F-FDG accumulation and LDHA expression has not been investigated. Methods: Retrospective analysis was conducted for 51 patients with lung adenocarcinomas who underwent 18F-FDG PET. The relationship between maximum standardized uptake value and the expression of LDHA, glucose transporter 1 (GLUT1), and hexokinase 2 (HK2) were examined. RNA interference was used to analyze the role of LDHA in tumor metabolism and growth in A549 cells. The AKT, also known as protein kinase B, pathway was also investigated to evaluate the molecular mechanisms of the relationship between LDHA expression and 18F-FDG uptake. Results: Maximum standardized uptake value was significantly higher in the LDHA high-expression group than the LDHA low-expression group (P = 0.018). GLUT1 expression in lung adenocarcinomas was positively correlated with 18F-FDG accumulation and LDHA expression whereas HK2 expression was not. Knockdown of LDHA led to a significant decrease in GLUT1 expression, 18F-FDG uptake, and cell proliferation. The activated form of AKT was also decreased after LDHA knockdown. Conclusion: LDHA increases 18F-FDG accumulation into non–small cell lung cancer, possibly by upregulation of GLUT1 expression but not HK2 expression. LDHA may modulate 18F-FDG uptake in lung adenocarcinomas via the AKT–GLUT1 pathway. These results indicate that 18F-FDG PET/CT may predict LDHA expression levels and response to anti-LDHA therapy in lung adenocarcinomas.